Glucuronides in anti-cancer therapy

Xi Chen, Bingyuan Wu, Peng George Wang

Research output: Contribution to journalArticle

43 Scopus citations

Abstract

Glucuronide prodrugs have shown promising efficacy in anti-cancer therapy due to their increased specificity and reduced systemic toxicity. The prodrugs can be used in prodrug monotherapy (PMT), which is based on elevated tumor β-glucuronidase activity. β-Glucuronidase activates the low-toxic prodrugs into highly cytotoxic agents specifically in the tumor site. The specificity of the prodrugs can be further improved by combined use with monoclonal antibodies against tumor-specific antigens, namely antibody-directed enzyme prodrug therapy (ADEPT); and the potency of the prodrugs can be greatly enhanced with the incorporation of an appropriate radionuclide in the combined chemo- and radio-therapy of cancer (CCRTC) strategy. The prodrugs can also be utilized to modify liposomes for efficient delivery of anti-cancer drugs.

Original languageEnglish (US)
Pages (from-to)139-150
Number of pages12
JournalCurrent Medicinal Chemistry - Anti-Cancer Agents
Volume3
Issue number2
DOIs
StatePublished - 2003
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Cancer Research
  • Pharmacology

Fingerprint Dive into the research topics of 'Glucuronides in anti-cancer therapy'. Together they form a unique fingerprint.

  • Cite this